EUVIMEDOpdag EUVIMED
Systematische ÜbersichtMetaanalyse

The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis

Wirkung von GLP-1-Rezeptoragonisten auf zirkulierende Entzündungsmarker bei Patient:innen mit Typ-2-Diabetes: systematische Übersichtsarbeit und Metaanalyse

Yifan Ren iD, Yuzhang Chen, Wenbin Zheng, Wen Kong iD, Yunfei Liao, Jiaoyue Zhang, Meng Wang, Tianshu Zeng

Diabetes, Obesity and Metabolism · 2025-07 · 27 (7) · 3607-3626

DOI: 10.1111/dom.16366 ↗

Auf einen Blick

Bei 52 RCTs mit 4.734 Patient:innen waren GLP-1-Rezeptoragonisten mit niedrigeren Entzündungsmarkern und höherem Adiponektin verbunden als Vergleichstherapien.

Fragestellung

Haben GLP-1-Rezeptoragonisten bei Typ-2-Diabetes antiinflammatorische Effekte auf zirkulierende Entzündungsmarker?

Methode

Systematische Übersichtsarbeit und Metaanalyse von RCTs; Suche in Medline, Embase, Cochrane Library und Web of Science.

Ergebnisse

52 RCTs (n = 4.734), medianes Follow-up 24 Wochen. Im Vergleich zu Placebo oder konventionellen Therapien sanken CRP, TNF-α, IL-6, IL-1β und Leptin; Adiponektin stieg. SMD: CRP −0,63, TNF-α −0,92, IL-6 −0,76, IL-1β −3,89, Leptin −0,67, Adiponektin 0,69.

Schlussfolgerung der Autor:innen

Die Metaanalyse zeigt, dass GLP-1-Rezeptoragonisten bei Typ-2-Diabetes signifikante antiinflammatorische Effekte haben.

Kernaussagen

  • CRP, TNF-α, IL-6, IL-1β und Leptin sanken unter GLP-1-RAs
  • Adiponektin stieg unter GLP-1-RAs
  • Vergleich mit Placebo oder konventionellen Therapien

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Systematische Übersicht in Diabetes, Obesity and Metabolism, published online on 2025-04-15. Written by Yifan Ren and 7 co-authors. Institution: Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Inflammation. Cited 64 times so far (Crossref); 140 references. Funded by: National Natural Science Foundation of China.

Auf einen BlickAbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

To investigate whether the antidiabetic agent glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) can exert anti‐inflammatory effects while lowering blood glucose, we performed a meta‐analysis and systematic review.

Methods

We searched 4 online databases (Medline, Embase, Cochrane Library and the Web of Science) for randomised controlled trials (RCTs) that examined changes after GLP‐1RAs intervention in commonly accepted biomarkers of inflammation: C‐reactive protein (CRP), tumour necrosis factor‐alpha (TNF‐α), interleukin‐6 (IL‐6), interleukin‐1β (IL‐1β), leptin, adiponectin, plasminogen activator inhibitor‐1 (PAI‐1), monocyte chemotactic protein‐1(MCP‐1) and advanced glycation end products (AGEs).

Results

This meta‐analysis included 52 eligible RCTs ( n = 4734) with a median follow‐up of 24 weeks, a mean age of 54.13 years, 44.46% females, body mass index (BMI) 29.80 kg/m 2 , glycated haemoglobin (HbA1c) 8.28% and diabetes duration 7.27 years. GLP‐1 RAs treatment, compared to placebo or conventional diabetes therapies (including oral medicine and insulin), resulted in significant reductions in CRP, TNF‐α, IL‐6, IL‐1β and leptin (standard mean difference [SMD] −0.63 [−1.03, −0.23]; SMD ‐0.92 [−1.57, −0.27]; SMD ‐0.76 [−1.32, −0.20], SMD ‐3.89 [−6.56, −1.22], SMD ‐0.67 [−1.09, −0.26], respectively), as well as significant increases in adiponectin (SMD 0.69 [0.19, 1.19]).

Conclusions

Our meta‐analysis demonstrates that GLP‐1 RAs exert significant anti‐inflammatory effects in patients with T2DM. Our findings provide important insights that may guide the therapeutic application of GLP‐1 RAs and inform the development of related therapies.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInflammationHumansBiomarkersRandomized Controlled Trials as TopicC-Reactive ProteinFemale

Author keywords

CRPGLP‐1 RAsIL‐6glucagon‐like peptide‐1 receptor agonistsinflammationmeta‐analysis

Substances

Glucagon-Like Peptide-1 Receptor AgonistsBiomarkersHypoglycemic AgentsC-Reactive Protein

Authors and institutions

  • Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Diabetes and Metabolic Disease Clinical Research Center of Hubei Province, Wuhan, China.
  • Hubei Key Laboratory of Metabolic Abnormalities and Vascular Aging, Wuhan, China.
  • Hubei Branch of National Center for Clinical Medical Research of Metabolic Diseases, Wuhan, China.

ORCID profiles: Yifan Ren, Wen Kong

Funding

  • National Natural Science Foundation of China

Cite

APA

Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025). The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 27(7), 3607-3626. https://doi.org/10.1111/dom.16366

Vancouver

Ren Y, Chen Y, Zheng W, Kong W, Liao Y, Zhang J, et al. The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2025;27(7):3607-3626. doi:10.1111/dom.16366

BibTeX
@article{Ren2025,
  author = {Ren, Yifan and Chen, Yuzhang and Zheng, Wenbin and Kong, Wen and Liao, Yunfei and Zhang, Jiaoyue and Wang, Meng and Zeng, Tianshu},
  title = {The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {7},
  pages = {3607--3626},
  doi = {10.1111/dom.16366}
}
Start for free →